Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies
S Huang, X Wang, Y Wang, Y Wang, C Fang, Y Wang… - Molecular Cancer, 2023 - Springer
Chimeric antigen receptor (CAR) T-cell therapy has made remarkable progress in cancer
immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical …
immunotherapy, but several challenges with unclear mechanisms hinder its wide clinical …
[HTML][HTML] Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies
H Lin, X Yang, S Ye, L Huang, W Mu - Biomedicine & Pharmacotherapy, 2024 - Elsevier
Chimeric antigen receptor T (CAR-T) cell therapy has shown promise in treating
hematological malignancies and certain solid tumors. However, its efficacy is often hindered …
hematological malignancies and certain solid tumors. However, its efficacy is often hindered …
[HTML][HTML] An anti-CD19/CTLA-4 switch improves efficacy and selectivity of CAR T cells targeting CD80/86-upregulated DLBCL
LF Prinz, T Riet, DF Neureuther, S Lennartz… - Cell Reports …, 2024 - cell.com
Chimeric antigen receptor T cell (CAR T) therapy is a potent treatment for relapsed/refractory
(r/r) B cell lymphomas but provides lasting remissions in only∼ 40% of patients and is …
(r/r) B cell lymphomas but provides lasting remissions in only∼ 40% of patients and is …
Harnessing the Transcriptional Signatures of CAR-T-Cells and Leukemia/Lymphoma Using Single-Cell Sequencing Technologies
YM Liao, SH Hsu, SS Chiou - International Journal of Molecular Sciences, 2024 - mdpi.com
Chimeric antigen receptor (CAR)-T-cell therapy has greatly improved outcomes for patients
with relapsed or refractory hematological malignancies. However, challenges such as …
with relapsed or refractory hematological malignancies. However, challenges such as …
[HTML][HTML] 急性B 淋巴细胞白血病CD19 CAR-T 细胞治疗后阳性复发的机制和挽救性治疗策略
卢聪， 徐佳， 梅恒 - Chinese Journal of Hematology, 2024 - pmc.ncbi.nlm.nih.gov
尽管嵌合抗原受体T (CAR-T) 细胞疗法改变了复发/难治急性B 淋巴细胞白血病(R/R B-ALL)
的治疗格局, 仍然有50% 患者在治疗后1 年内复发, 且60% 左右为阳性复发. 导致CAR-T …
的治疗格局, 仍然有50% 患者在治疗后1 年内复发, 且60% 左右为阳性复发. 导致CAR-T …
Adaptable leukemia cells resisting CAR T-cell attack via B-cell activation
Z Zhao, JJ Melenhorst - Cancer Immunology Research, 2022 - AACR
Chimeric antigen receptor (CAR) T-cell therapy has achieved remarkable milestones in the
treatment of B-cell malignancies. However, cancer cells frequently survive CAR T-cell killing …
treatment of B-cell malignancies. However, cancer cells frequently survive CAR T-cell killing …
[HTML][HTML] Single-cell genomics-based immune and disease monitoring in blood malignancies
Achieving long-term disease control using therapeutic immunomodulation is a long-standing
concept with a strong tradition in blood malignancies. Besides allogeneic hematopoietic …
concept with a strong tradition in blood malignancies. Besides allogeneic hematopoietic …